MiMedx Group, Inc., a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts. The company's proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. Its biomaterial platform technologies include AmnioFix and EpiFix that are tissue technologies processed from human amniotic membrane derived from donated placental tissue for homologous applications; OrthoFlo, an amniotic fluid-derived allograft for homologous applications; Physio, a bone grafting material comprising 100% bone tissue with no added carrier; and CollaFix, a technology platform derived from collagen fiber technology designed to mimic the natural composition, structure, and mechanical properties of musculoskeletal tissues to augment their repair. The company also offers EpiCord, an umbilical cord allograft that provides a connective tissue matrix to replace or supplement damaged or inadequate integumental tissue; AmnioCord, an umbilical cord allograft that offers a protective environment for the healing process; and AmnioFill, a cellular tissue matrix allograft that enhances healing. Its products have applications in the areas of wound care, burns, surgery, orthopedics, spine, sports medicine, ophthalmology, and dentistry. The company sells its products through direct sales force, and independent stocking distributors, and third party representatives in the United States, as well as independent distributors internationally. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MDXG
CUSIPN/A
Phone770-651-9100
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E Ratio25.29
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$245.01 million
Price / Sales2.45
Cash Flow$0.1848 per share
Price / Cash29.22
Book Value$1.21 per share
Price / Book4.46
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares111,040,000
Market Cap$589.59 million
MiMedx Group (NASDAQ:MDXG) Frequently Asked Questions
What is MiMedx Group's stock symbol?
MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."
How will MiMedx Group's stock buyback program work?
MiMedx Group declared that its board has approved a stock buyback plan on Wednesday, December 13th 2017, which authorizes the company to buyback $10,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase shares of its stock through open market purchases. Shares buyback plans are usually a sign that the company's management believes its shares are undervalued.
How were MiMedx Group's earnings last quarter?
MiMedx Group Inc (NASDAQ:MDXG) posted its quarterly earnings data on Thursday, October, 26th. The medical equipment provider reported $0.08 earnings per share for the quarter, meeting the Zacks' consensus estimate of $0.08. The medical equipment provider had revenue of $84.60 million for the quarter, compared to analyst estimates of $84.60 million. MiMedx Group's quarterly revenue was up 31.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.06 earnings per share. View MiMedx Group's Earnings History.
When is MiMedx Group's next earnings date?
What price target have analysts set for MDXG?
4 analysts have issued 12 month target prices for MiMedx Group's shares. Their forecasts range from $9.00 to $21.00. On average, they anticipate MiMedx Group's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 201.3% from the stock's current price. View Analyst Price Targets for MiMedx Group.
What is the consensus analysts' recommendation for MiMedx Group?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MiMedx Group in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MiMedx Group.
What are Wall Street analysts saying about MiMedx Group stock?
Here are some recent quotes from research analysts about MiMedx Group stock:
- 1. Needham & Company LLC analysts commented, "This morning (3/15/18), MDXG issued a press release announcing: 1) management expects 1Q18 revenue to exceed the high end of their guidance range and reiterates their 2018 guidance and 2) the U.S. Department of Justice (DOJ) is reviewing the SEC investigation matters. While MDXG’s business appears to be performing well despite the controversy swirling around the company, we believe investors may continue to heavily discount the fundamentals until more is known about the outcome of the Audit Committee’s investigation, the SEC investigation, and the DOJ review." (3/15/2018)
- 2. According to Zacks Investment Research, "MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant. " (12/8/2017)
Are investors shorting MiMedx Group?
MiMedx Group saw a increase in short interest during the month of September. As of September 28th, there was short interest totalling 59,382,334 shares, an increase of 0.6% from the September 14th total of 59,754,963 shares. Based on an average daily volume of 3,558,877 shares, the short-interest ratio is presently 16.7 days. Currently, 57.9% of the shares of the stock are short sold. View MiMedx Group's Current Options Chain.
Who are some of MiMedx Group's key competitors?
Some companies that are related to MiMedx Group include Glaukos (GKOS), Tandem Diabetes Care (TNDM), Irhythm Technologies (IRTC), Mazor Robotics (MZOR), Nevro (NVRO), Atrion (ATRI), Luminex (LMNX), Cardiovascular Systems (CSII), K2M Group (KTWO), Tactile Systems Technology (TCMD), Cryolife (CRY), AtriCure (ATRC), Orthofix Medical (OFIX), OraSure Technologies (OSUR) and Cerus (CERS).
Who are MiMedx Group's key executives?
MiMedx Group's management team includes the folowing people:
- Ms. Alexandra O. Haden, Gen. Counsel and Sec. (Age 43)
- Mr. David J. Coles, Interim Chief Exec. Officer (Age 53)
- Mr. Edward J. Borkowski, Interim Chief Financial Officer (Age 60)
- Dr. Thomas J. Koob, Chief Scientific Officer (Age 69)
- Mr. Thornton A. Kuntz Jr., Sr. VP of Admin. (Age 64)
Who are MiMedx Group's major shareholders?
Which major investors are selling MiMedx Group stock?
How do I buy shares of MiMedx Group?
Shares of MDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MiMedx Group's stock price today?
One share of MDXG stock can currently be purchased for approximately $5.31.
How big of a company is MiMedx Group?
MiMedx Group has a market capitalization of $589.59 million and generates $245.01 million in revenue each year.
What is MiMedx Group's official website?
How can I contact MiMedx Group?
MiMedx Group's mailing address is 1775 W OAK COMMONS COURT NE, MARIETTA GA, 30062. The medical equipment provider can be reached via phone at 770-651-9100 or via email at [email protected]
MarketBeat Community Rating for MiMedx Group (NASDAQ MDXG)
MarketBeat's community ratings are surveys of what our community members think about MiMedx Group and other stocks. Vote "Outperform" if you believe MDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDXG will underperform the S&P 500 over the long term. You may vote once every thirty days.
